Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-s-1587119th CongressWALLET
Fair Prescription Drug Prices for Americans Act
Sponsored By: Senator Hawley, Josh [R-MO]
Introduced
Summary
This bill would create an international reference pricing system that caps U.S. retail list prices for prescription drugs and biological products. It would require annual manufacturer price reporting, direct the Health and Human Services Secretary to calculate a yearly average across Canada, France, Germany, Italy, Japan, and the United Kingdom, and allow per-unit civil penalties equal to ten times the price difference for violations.
Show full summary
- Families and patients: Limits the U.S. retail list price for covered drugs and biologics so it cannot exceed the average retail list price across six named countries.
- Drug manufacturers: Must submit annual list-price data for the U.S. and each of the six countries and face civil monetary penalties equal to ten times the per-unit price difference if they exceed the cap.
- Health agencies: The Health and Human Services Secretary would calculate the annual foreign average using manufacturer submissions and public filings and may issue guidance and regulations to implement the system.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Lower drug list prices for Americans
This bill would cap the U.S. retail list price for a drug or biological product so it cannot be higher than the average list price in six countries (Canada, France, Germany, Italy, Japan, and the UK). The Secretary of Health and Human Services would calculate that foreign average every year using data from makers and public filings. Drug makers would have to submit annual list prices for the U.S. and each of the six countries. If a maker sold above the cap, the Secretary could charge a civil penalty equal to ten times the per-unit price difference, charged for each unit sold. If manufacturers lower prices to the cap, households could save the per-unit difference times how many units they buy. If enacted, the Secretary would issue guidance and rules to implement this requirement.
Sponsors & CoSponsors
Sponsor
Hawley, Josh [R-MO]
MO • R
Cosponsors
Sen. Welch, Peter [D-VT]
VT • D
Sponsored 5/5/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov